Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 6/2012

Open Access 01-06-2012 | Article

Dynamics of interferon-gamma release assay and cytokine profiles in blood and respiratory tract specimens from mice with tuberculosis and the effect of therapy

Authors: J. E. M. de Steenwinkel, G. J. de Knegt, M. T. ten Kate, H. A. Verbrugh, T. H. M. Ottenhoff, I. A. J. M. Bakker-Woudenberg

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 6/2012

Login to get access

Abstract

There are limitations on diagnostic methods to differentiate between active and latent tuberculosis (TB), and the prediction of latent progression to TB disease is yet complex. Traditionally, tuberculosis-specific host immune response was visualized using the tuberculin skin test. Nowadays, IFN-γ release assays (IGRA) provide a more specific and sensitive tool, by which exposure to Mtb could be determined. However, the merit of IGRA aids in diagnosing active TB is yet unclear. We adapted IGRA for use in mice, and quantifying bead-based flow cytometry techniques were used to assess cytokine profiles during the course of untreated infection and to investigate the value of IGRA and cytokines as biomarkers for therapy response. High variability of IGRA results during progression of active TB infection related to various phases of infection was obtained. However, a significant decrease in IGRA results and in levels of IFN-γ, IL-17, IP-10 or MIG was observed and appeared to be associated with successful therapy. This outcome does not support the value of IGRA to accurately diagnose active TB or to monitor infection progression. However, IGRA proved to be a useful biomarker to monitor therapy success. In addition, different cytokines might serve as biomarkers.
Literature
1.
go back to reference Arko-Mensah J, Rahman MJ, Julian E et al (2009) Increased levels of immunological markers in the respiratory tract but not in serum correlate with active pulmonary mycobacterial infection in mice. Clin Microbiol Infect 15:777–786PubMedCrossRef Arko-Mensah J, Rahman MJ, Julian E et al (2009) Increased levels of immunological markers in the respiratory tract but not in serum correlate with active pulmonary mycobacterial infection in mice. Clin Microbiol Infect 15:777–786PubMedCrossRef
2.
go back to reference Diel R, Loddenkemper R, Nienhaus A (2009) Evidence based comparison of commercial interferon-gamma release assays for detecting active tuberculosis—a meta-analysis. Chest 137(4):952–968 Diel R, Loddenkemper R, Nienhaus A (2009) Evidence based comparison of commercial interferon-gamma release assays for detecting active tuberculosis—a meta-analysis. Chest 137(4):952–968
3.
go back to reference Jiang J, Shi HZ, Liang QL et al (2007) Diagnostic value of interferon-gamma in tuberculous pleurisy: a metaanalysis. Chest 131:1133–1141PubMedCrossRef Jiang J, Shi HZ, Liang QL et al (2007) Diagnostic value of interferon-gamma in tuberculous pleurisy: a metaanalysis. Chest 131:1133–1141PubMedCrossRef
4.
go back to reference Lange C, Pai M, Drobniewski F et al (2009) Interferon-gamma release assays for the diagnosis of active tuberculosis: sensible or silly? Eur Respir J 33:1250–1253PubMedCrossRef Lange C, Pai M, Drobniewski F et al (2009) Interferon-gamma release assays for the diagnosis of active tuberculosis: sensible or silly? Eur Respir J 33:1250–1253PubMedCrossRef
5.
go back to reference Pai M, Zwerling A, Menzies D (2008) Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149:177–84PubMed Pai M, Zwerling A, Menzies D (2008) Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149:177–84PubMed
6.
go back to reference National Tuberculosis Controllers Association and Centers for Disease Control and Prevention (CDC) (2005) Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep 54:1–47 National Tuberculosis Controllers Association and Centers for Disease Control and Prevention (CDC) (2005) Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep 54:1–47
7.
go back to reference Jafari C, Thijsen S, Sotgiu G et al (2009) Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study. Am J Respir Crit Care Med 180:666–673PubMedCrossRef Jafari C, Thijsen S, Sotgiu G et al (2009) Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study. Am J Respir Crit Care Med 180:666–673PubMedCrossRef
8.
go back to reference De Steenwinkel JE, De Knegt GJ, Ten Kate MT et al (2009) Immunological parameters to define infection progression and therapy response in a well-defined tuberculosis model in mice. Int J Immunopathol Pharmacol 22:723–734PubMed De Steenwinkel JE, De Knegt GJ, Ten Kate MT et al (2009) Immunological parameters to define infection progression and therapy response in a well-defined tuberculosis model in mice. Int J Immunopathol Pharmacol 22:723–734PubMed
9.
go back to reference Bakker-Woudenberg IA (2003) Experimental models of pulmonary infection. J Microbiol Methods 54:295–313PubMedCrossRef Bakker-Woudenberg IA (2003) Experimental models of pulmonary infection. J Microbiol Methods 54:295–313PubMedCrossRef
10.
go back to reference Rosenthal IM, Zhang M, Williams KN et al (2007) Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 4:e344PubMedCrossRef Rosenthal IM, Zhang M, Williams KN et al (2007) Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 4:e344PubMedCrossRef
11.
go back to reference Shafiani S, Tucker-Heard G, Kariyone A et al (2010) Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis. J Exp Med 207:1409–1420PubMedCrossRef Shafiani S, Tucker-Heard G, Kariyone A et al (2010) Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis. J Exp Med 207:1409–1420PubMedCrossRef
12.
go back to reference Joosten SA, van Meijgaarden KE, Savage ND et al (2007) Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc Natl Acad Sci USA 104:8029–8034PubMedCrossRef Joosten SA, van Meijgaarden KE, Savage ND et al (2007) Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc Natl Acad Sci USA 104:8029–8034PubMedCrossRef
13.
go back to reference Sahiratmadja E, Alisjahbana B, de Boer T et al (2007) Dynamic changes in pro- and anti-inflammatory cytokine profiles and gamma interferon receptor signaling integrity correlate with tuberculosis disease activity and response to curative treatment. Infect Immun 75:820–829PubMedCrossRef Sahiratmadja E, Alisjahbana B, de Boer T et al (2007) Dynamic changes in pro- and anti-inflammatory cytokine profiles and gamma interferon receptor signaling integrity correlate with tuberculosis disease activity and response to curative treatment. Infect Immun 75:820–829PubMedCrossRef
14.
go back to reference Hooper CE, Lee YC, Maskell NA (2009) Interferon-gamma release assays for the diagnosis of TB pleural effusions: hype or real hope? Curr Opin Pulm Med 15:358–365PubMedCrossRef Hooper CE, Lee YC, Maskell NA (2009) Interferon-gamma release assays for the diagnosis of TB pleural effusions: hype or real hope? Curr Opin Pulm Med 15:358–365PubMedCrossRef
15.
go back to reference Lee SW, Lee CT, Yim JJ (2010) Serial interferon-gamma release assays during treatment of active tuberculosis in young adults. BMC Infect Dis 10:300PubMedCrossRef Lee SW, Lee CT, Yim JJ (2010) Serial interferon-gamma release assays during treatment of active tuberculosis in young adults. BMC Infect Dis 10:300PubMedCrossRef
16.
go back to reference Gonzalez-Juarrero M, Kingry LC, Ordway DJ et al (2009) Immune response to Mycobacterium tuberculosis and identification of molecular markers of disease. Am J Respir Cell Mol Biol 40:398–409PubMedCrossRef Gonzalez-Juarrero M, Kingry LC, Ordway DJ et al (2009) Immune response to Mycobacterium tuberculosis and identification of molecular markers of disease. Am J Respir Cell Mol Biol 40:398–409PubMedCrossRef
17.
go back to reference Beamer GL, Flaherty DK, Vesosky B et al (2008) Peripheral blood gamma interferon release assays predict lung responses and Mycobacterium tuberculosis disease outcome in mice. Clin Vaccine Immunol 15:474–483PubMedCrossRef Beamer GL, Flaherty DK, Vesosky B et al (2008) Peripheral blood gamma interferon release assays predict lung responses and Mycobacterium tuberculosis disease outcome in mice. Clin Vaccine Immunol 15:474–483PubMedCrossRef
Metadata
Title
Dynamics of interferon-gamma release assay and cytokine profiles in blood and respiratory tract specimens from mice with tuberculosis and the effect of therapy
Authors
J. E. M. de Steenwinkel
G. J. de Knegt
M. T. ten Kate
H. A. Verbrugh
T. H. M. Ottenhoff
I. A. J. M. Bakker-Woudenberg
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 6/2012
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-011-1428-2

Other articles of this Issue 6/2012

European Journal of Clinical Microbiology & Infectious Diseases 6/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.